Neuland Laboratories Limited has informed the Exchange regarding 'Update on Outcome of Board meeting and Change in Directorate disclosures regarding appointment of additional director .Please note that there was a typographical error in the subject line under Disclosure B of the Outcome of Board Meeting intimated on July 31, 2025. It should be read as Appointment, instead of Reappointment, as under: B. Appointment of Dr. Ravi Shankar Gopinath (DIN: 00803847) as an Additional Director of the Company
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neuland Laboratories has issued a correction to its July 31, 2025 Board meeting outcome disclosure. A typographical error in the subject line under Disclosure B has been fixed — the word 'Reappointment' should be read as 'Appointment.' The correction confirms that Dr. Ravi Shankar Gopinath (DIN: 00803847) has been appointed as an Additional Director of the company. No other changes have been made to the original disclosures. The company has apologized for the inconvenience caused by the error.
This is a minor administrative correction with no material change to the substance of the original disclosure. Shareholders should note the accurate wording — Dr. Gopinath is a new appointment as Additional Director, not a reappointment of an existing director. No expected impact on stock price.